Shopping Cart 0
Cart Subtotal
USD 0

Zosano Pharma Corp (ZSAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Zosano Pharma Corp (Zosano Pharma), formerly ZP Holdings Inc, is a clinical stage biopharmaceutical company that develops proprietary transdermal delivery system. The company develops a transdermal microneedle patch system to deliver its drug formulations through the skin for the treatment of a variety of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. Zosano Pharma's lead product candidate, ADAM Zolmitriptan (M207), is a drug which is used orally and nasally to treat acute migraine. The company works in partnership with other contract manufacturing organizations for clinical and commercial development of its products. Zosano Pharma is headquartered in Fremont, California, the US.

Zosano Pharma Corp (ZSAN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Zosano Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Zosano Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Zosano Pharma Secures USD3.03 Million in Venture Funding 12

Equity Offering 13

Zosano Pharma Raises USD50 Million in Public Offering of Shares 13

Zosano Pharma to Raise up to USD35 Million in Private Placement of Shares 15

Zosano Pharma Raises USD29.3 Million in Public Offering of Common Stock 16

Zosano Pharma Raises USD7.5 Million in Private Placement of Shares and Warrants 17

Zosano Pharma Completes Underwriter's Exercise of Over-Allotment Option of IPO for USD1.2 Million 18

Debt Offering 20

Zosano Pharma Raises USD1.3 Million in Private Placement of 8% Notes Due 2017 20

Zosano Pharma Raises USD2.5 Million in Private Placement of 8% Notes Due 2014 21

Zosano Pharma Raises USD3 Million in Private Placement of 8% Notes Due 2014 22

Zosano Pharma Corp-Key Competitors 23

Zosano Pharma Corp-Key Employees 24

Zosano Pharma Corp-Locations And Subsidiaries 25

Head Office 25

Recent Developments 26

Financial Announcements 26

Aug 09, 2018: Zosano Pharma reports second quarter 2018 financial results and operational update 26

May 15, 2018: Zosano Pharma Announces First Quarter 2018 Financial Results 28

Mar 12, 2018: Zosano Pharma Announces Fourth Quarter and Fiscal Year 2017 Financial Results 29

Nov 09, 2017: Zosano Pharma Reports Third Quarter 2017 Financial Results and Operational Update 30

Aug 10, 2017: Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update 31

May 09, 2017: Zosano Reports First Quarter 2017 Financial Results and Announces Management Changes 32

Mar 01, 2017: Zosano Pharma Reports Fourth Quarter and Fiscal 2016 Financial Results and Business Update 34

Corporate Communications 35

Dec 15, 2017: Zosano Announces Resignation of Bruce Steel from Board of Directors 35

Oct 04, 2017: Zosano Appoints Kenneth Greathouse to Board of Directors 36

Jun 14, 2017: Zosano Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 37

Product News 38

09/13/2017: Zosano Presents Data from ZOTRIP Study at International Headache Society 38

06/12/2017: Zosano Presents Additional Data from ZOTRIP Study at American Headache Society, Demonstrating Positive Results for Pain Freedom and Sustained Pain Freedom 40

06/01/2017: Zosano to Present Migraine Data at Three Industry-Leading Conferences 42

Clinical Trials 43

Jul 31, 2017: Zosano Announces Publication of Positive Phase 1 Data of Zolmitriptan Delivery In Future Medicines Pain Management Journal 43

Jun 26, 2017: Zosano Pharma Announces Outcome of End of Phase 2 Meetings with FDA 44

Feb 13, 2017: Zosano Pharma Announces 3.8mg Dose of M207, its Novel Transdermal Therapeutic, Meets Both Co-primary Endpoints in the ZOTRIP Pivotal Efficacy Trial in Migraine 45

Jan 05, 2017: Zosano Pharma Announces Last Subject Treated in its Migraine Pivotal Trial 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Zosano Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Zosano Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Zosano Pharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Zosano Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10

Zosano Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Zosano Pharma Secures USD3.03 Million in Venture Funding 12

Zosano Pharma Raises USD50 Million in Public Offering of Shares 13

Zosano Pharma to Raise up to USD35 Million in Private Placement of Shares 15

Zosano Pharma Raises USD29.3 Million in Public Offering of Common Stock 16

Zosano Pharma Raises USD7.5 Million in Private Placement of Shares and Warrants 17

Zosano Pharma Completes Underwriter's Exercise of Over-Allotment Option of IPO for USD1.2 Million 18

Zosano Pharma Raises USD1.3 Million in Private Placement of 8% Notes Due 2017 20

Zosano Pharma Raises USD2.5 Million in Private Placement of 8% Notes Due 2014 21

Zosano Pharma Raises USD3 Million in Private Placement of 8% Notes Due 2014 22

Zosano Pharma Corp, Key Competitors 23

Zosano Pharma Corp, Key Employees 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Zosano Pharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.